Orlistat

Orlistat

CAS:96829-58-2
Molecular formula: C29H53NO5
Molecular weight: 495.7348
Assay: 99.6%
Boiling point: 615.9°C at 760 mmHg
Flash point: 326.3°C
Appearance: Off white powder
Description:

Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. It is marketed as a prescription drug under the trade name  by Roche in most countries, and is sold over-the-counter as by GlaxoSmithKline in the United Kingdom and the United States. Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.

Application:
 
The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data from clinical trials suggest that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2-3 kilograms (4.4-6.6 lb) more than those not taking the drug over the course of a year.Orlistat also modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes, whether due to weight loss itself or to other effects; in a large randomized controlled trial, orlistat was found to reduce the incidence of diabetes by nearly 40% in obese people.
 

COA:
 

TESTS Specificatione Results
Description White or almost crystalline powder White crystalline powder
Identification IR Conforms
Specific rotation -33 -35° -34°
Loss on drying <0.5% 0.35%
Melting point 42-45ºC 42-44ºC
Water <=2.0% 0.25%
Residual solvents n-hexane<=290ppm
n-heptane<=5000ppm
20ppm
1260ppm
Assay(HPLC) >=96.0%(ON DRY BASIS) 97.4%

 
 
Functiong & Usage

1) Usage:
 
Combined with micro low-calorie diet for obese and overweight participants including those already obesity-related risk factors of patients with long-term treatment. With long-term weight control (weight loss, maintain weight rebound and prevention) curative effect.
 
Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. It is marketed as a prescription drug under the trade name by Roche in most countries, and is sold over-the-counter as by GlaxoSmithKline in the United Kingdom and the United States.Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.
 
 
2) Medical uses:
 
Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body fat.After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost.
 
The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%).Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).